Secukinumab 2‐weekly vs. 4‐weekly dosing in patients with plaque‐type psoriasis: results from the randomized GAIN study*-Reference-Cited by-同舟云学术

Secukinumab 2‐weekly vs. 4‐weekly dosing in patients with plaque‐type psoriasis: results from the randomized GAIN study*

Published:2020-11-18 Issue:5 Volume:184 Page:849-856
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Reich K.¹^ORCID,Körber A.²,Mrowietz U.³^ORCID,Sticherling M.⁴^ORCID,Sieder C.⁵,Früh J.⁶,Bachhuber T.⁶

Affiliation:

1. Translational Research in Inflammatory Skin Diseases Institute for Health Services Research in Dermatology and NursingUniversity Medical Center Hamburg‐Eppendorf, and Skinflammation^® Center Hamburg Germany

2. Department of Dermatology University Hospital Essen Essen Germany

3. Klinik für Dermatologie Venerologie und AllergologieUniversitätsklinikum Schleswig‐Holstein Kiel Germany

4. Department of Dermatology Universitätsklinikum Erlangen Erlangen Germany

5. Novartis Pharma GmbH Nürnberg Germany

6. Novartis Pharma AG Basel Switzerland

Funder

Novartis Pharma

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.19398

Reference21 articles.

1. Implementing treatment goals for successful long-term management of psoriasis

2. Definition of treatment goals for moderate to severe psoriasis: a European consensus

3. PASI90 response: the new standard in therapeutic efficacy for psoriasis

4. European Medicines Agency.Clinical investigation of medicinal products indicated for the treatment of psoriasis. Available at:https://www.ema.europa.eu/en/clinical‐investigation‐medicinal‐products‐indicated‐treatment‐psoriasis(last accessed 13 July 2020).

5. Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: An analysis of Japanese clinical trials of infliximab

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment;Rheumatology;2024-08-12

2. Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry;Archives of Dermatological Research;2024-06-08

3. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Moderate-to-Severe Psoriasis;Clinical Pharmacokinetics;2024-01-27

4. A systematic review investigating at what proportion clinical images are shared in prospective randomized controlled trials involving patients with psoriasis and biological agents;Journal of Dermatological Treatment;2023-11-15

5. Optimization of secukinumab dose regimens in patients with moderate-to-severe plaque psoriasis via exposure-response modeling;Expert Review of Clinical Pharmacology;2023-09-22